Menopause Hormone Therapy (HRT): Lab Tests You Need Before and During Treatment

Hormone replacement therapy (HRT) has become one of the most talked-about topics in women's health — and for good reason. For millions of women experiencing menopause symptoms, HRT can be transformative. But starting HRT without baseline lab testing is like adjusting a prescription without knowing your starting dose. Lab work before, during, and after starting HRT is essential for safe and effective treatment.

Whether you're exploring HRT for the first time or already on therapy and wondering if your dose is right, this guide covers exactly which lab tests matter and why.

Why Lab Testing Matters for HRT

Menopause hormone therapy isn't one-size-fits-all. The type, dose, and route of hormones that work for one woman may be completely wrong for another. According to the 2022 Hormone Therapy Position Statement from The North American Menopause Society (NAMS), individualized therapy guided by symptoms and clinical assessment — including lab monitoring — produces the best outcomes.

Lab testing serves three critical purposes:

1. Establishing a baseline before starting therapy 2. Optimizing dosing once therapy begins 3. Monitoring safety markers over time

Essential Lab Tests Before Starting HRT

1. Estradiol (E2)

Estradiol is the primary estrogen your ovaries produce and the form most commonly replaced in HRT. Baseline levels confirm menopausal status and provide a reference point for dosing.

• Premenopausal range: 30-400 pg/mL (varies by cycle day)
• Postmenopausal (no HRT): Typically below 20 pg/mL
• Optimal on HRT: Most practitioners target 50-150 pg/mL depending on symptoms and route of administration

2. FSH (Follicle-Stimulating Hormone)

FSH rises as ovarian function declines. A high FSH confirms menopause and provides context for estrogen levels.

• Premenopausal: 3-10 mIU/mL (follicular phase)
• Postmenopausal: Typically above 30 mIU/mL
• On HRT: FSH often decreases but doesn't need to reach premenopausal levels

3. Progesterone

If you have a uterus, you need progesterone alongside estrogen to protect the endometrial lining. Baseline testing confirms you're not already supplementing or producing significant progesterone.

4. Total and Free Testosterone

Testosterone declines by approximately 50% between your 20s and menopause (Davis & Wahlin-Jacobsen, 2015). Many menopausal symptoms — low libido, fatigue, brain fog, muscle loss — are partially driven by testosterone decline.

• Premenopausal total testosterone: 15-70 ng/dL
• Postmenopausal: Often below 20 ng/dL
• SHBG should be tested alongside, as it determines how much testosterone is biologically active

5. Complete Thyroid Panel

Thyroid symptoms overlap significantly with menopause symptoms — and thyroid dysfunction becomes more common after 40. Ruling out or identifying thyroid issues before starting HRT prevents misattribution of symptoms.

• TSH — screening marker
• Free T4 and Free T3 — actual hormone levels
• TPO antibodies — Hashimoto's screening (affects up to 10% of postmenopausal women)

6. Metabolic Panel

Menopause increases cardiovascular and metabolic risk. These baseline markers are essential:

• Fasting insulin — the earliest marker of metabolic dysfunction
• Fasting glucose and HbA1c — diabetes screening
• Lipid panel — total cholesterol, LDL, HDL, triglycerides
• hsCRP — inflammatory marker linked to cardiovascular risk

Estrogen is cardioprotective, and part of HRT's benefit is metabolic — but you need a baseline to track improvement (Manson et al., 2013).

7. Vitamin D and Ferritin

Both are commonly deficient in menopausal women and affect bone health, energy, mood, and immune function. Optimizing these alongside HRT improves outcomes.

• Vitamin D goal: 40-60 ng/mL
• Ferritin goal: 50-100 ng/mL

Monitoring Labs While on HRT

Once you've started HRT, follow-up testing ensures your doses are correct and your body is responding safely.

6-8 Weeks After Starting or Adjusting Dose

This is the sweet spot for retesting. Hormone levels have typically stabilized by this point.

Recheck: - Estradiol — is it in the target range for your route? - Progesterone (if supplementing) — adequate for endometrial protection? - Testosterone (if supplementing) — in female physiological range? - SHBG — oral estrogen raises SHBG, which can bind testosterone and reduce its effectiveness

Route-Specific Considerations

The route of administration affects which labs matter most:

Oral estrogen: - Raises SHBG significantly (first-pass liver effect) - Can increase clotting factors — check SHBG as a proxy for hepatic effect - May raise triglycerides

Transdermal estrogen (patches, gels, creams): - Bypasses the liver, minimal effect on SHBG and clotting factors - Generally preferred for women with cardiovascular risk factors or migraines (Scarabin, 2018) - Estradiol levels can be tested reliably via blood draw

Pellets/injections: - Can produce supraphysiological peaks — timing of blood draw relative to insertion/injection matters - Test at trough (just before next dose) for the most accurate picture

Every 6-12 Months Ongoing

Once stable, annual monitoring should include:

• Estradiol and progesterone — confirming ongoing adequacy
• Testosterone and SHBG — especially if libido or energy symptoms persist
• Thyroid panel — thyroid needs can shift with HRT
• Metabolic markers — fasting insulin, glucose, HbA1c, lipids
• Vitamin D — ongoing optimization
• CBC — basic blood health monitoring

Red Flags That Suggest Your HRT Needs Adjustment

Your labs and symptoms together tell the story. Watch for these signals:

• Persistent hot flashes or night sweats — estradiol may be too low
• Breast tenderness or bloating — estradiol may be too high, or progesterone type/dose needs adjustment
• Mood symptoms (anxiety, irritability) — check progesterone levels and type; consider testosterone
• Low libido despite adequate estrogen — testosterone is likely too low or SHBG too high
• Fatigue and brain fog — recheck thyroid, testosterone, and metabolic markers
• Breakthrough bleeding — evaluate endometrial thickness; adjust progesterone

What Optimal Levels Look Like on HRT

While ranges vary by practitioner and individual, here are general targets many integrative and menopause-specialist providers use:

• Estradiol: 50-150 pg/mL (symptom-dependent)
• Progesterone: Variable by type; oral micronized progesterone levels are difficult to measure accurately via blood
• Total testosterone: 30-60 ng/dL (if supplementing)
• Free testosterone: 1-5 pg/mL
• SHBG: 30-80 nmol/L (watch for elevations above 100 on oral estrogen)
• TSH: 0.5-2.5 mIU/L (optimal, not just "normal")
• Vitamin D: 40-60 ng/mL

The Bottom Line

HRT can be life-changing — but it works best when guided by data. Baseline lab testing before starting, follow-up testing at 6-8 weeks, and ongoing annual monitoring ensure you're on the right type, dose, and route for your body. Don't settle for a prescription without a lab panel to guide it.

Take the Quiz

Not sure which hormones to test or whether HRT might be right for you? Take our free Biomarker Quiz to get personalized lab test recommendations based on your symptoms. It takes less than 2 minutes — and it's the smartest first step toward informed hormone therapy.

References

• The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767-794.
• Davis, S. R., & Wahlin-Jacobsen, S. (2015). Testosterone in women — the clinical significance. The Lancet Diabetes & Endocrinology, 3(12), 980-992.
• Manson, J. E., et al. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA, 310(13), 1353-1368.
• Scarabin, P. Y. (2018). Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis. Climacteric, 21(4), 341-345.
• Slopien, R., et al. (2018). Menopause and diabetes: EMAS clinical guide. Maturitas, 117, 6-10.
• Stuenkel, C. A., et al. (2015). Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 100(11), 3975-4011.